



RNS Number : 5649X
Integrated Diagnostics Holdings PLC
20 December 2019

Integrated Diagnostics Holdings Plc

20 December 2019

Appointment of Investec and Panmure Gordon as Joint Corporate Brokers

(Cairo and London) - Integrated Diagnostics Holdings ("IDH" or "the Company"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, is pleased to announce the appointment of Investec Bank plc and Panmure Gordon (UK) Limited as joint corporate brokers to the Company with immediate effect.

-Ends-

Contacts

IDH

+20 (0)2 3345 5530

Sherif El-Ghamrawi, Investor Relations
Director

+20 (0)10 0447 8699
sherif.elghamrawi@idhcorp.com

Investec Bank plc

+44 (0)207 597 5970

Sara Hale
Daniel Adams
Duncan Wilson

Panmure Gordon

+44 (0)207 886 2500

Freddy Crossley
Emma Earl

James Stearns

About Integrated Diagnostics Holdings

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Scan (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 1,400 diagnostics tests. From its base of 424 branches as of 30 June 2019, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern and African markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015.

IDH's forward-looking strategy rests on leveraging its established business model to achieve four key strategic goals, namely: (1) continue to expand customer reach; (2) increase the number of tests per patient; (3) expand into new geographic markets through selective, value-accretive acquisitions; and (4) introduce new medical services by leveraging the Group's network and reputable brand position. Learn more at idhcorp.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPFMMMZRLZGLZM